Methylphenidate Viatris Lp

Methylphenidate, the active ingredient in Methylphenidate Viatris Lp, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children and adults.

GNH USA supplies Methylphenidate Viatris Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is a central nervous system stimulant indicated for disorders affecting attention and wakefulness. - Attention deficit hyperactivity disorder (ADHD) in children: improves attention and reduces hyperactive behavior. - Attention deficit hyperactivity disorder (ADHD) in adults: enhances concentration and decreases impulsivity. - Narcolepsy: lessens daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea. - Increased heart rate: tachycardia without other symptoms. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Hypertension: significant elevation of blood pressure. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Psychosis: hallucinations or delusional thinking. - Seizures: convulsive episodes, especially in predisposed individuals. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Peripheral vasculitis: inflammation of small blood vessels.

Before prescribing methylphenidate, clinicians should consider several safety measures. - Assess cardiovascular status: evaluate blood pressure and heart rate prior to initiation. - Monitor growth in children: regularly track weight and height. - Avoid use in patients with known hypersensitivity to methylphenidate. - Use caution with concomitant MAO inhibitors: ensure an appropriate wash‑out period. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Methylphenidate can interact with various medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular stimulation. - Antihypertensive agents: potential reduction of blood‑pressure control. - Other CNS stimulants: additive sympathomimetic effects.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): possible serotonergic excess. - Antacids: may alter gastrointestinal absorption. - Alcohol: can enhance central nervous system depression.